Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.68 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.59 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8568429 | 1.00 | EPHX2 (0.68) | EPHX2MTNR1AMTNR1BMAPK1HDAC8 | |
| SCHEMBL8568435 | 1.00 | EPHX2 (0.68) | EPHX2MTNR1AMTNR1BMAPK1HDAC8 | |
| SCHEMBL429344 | 0.86 | EPHX2 (0.66) | EPHX2MTNR1AMTNR1BMAPK1HDAC8 | |
| SCHEMBL8561739 | 0.85 | EPHX2 (0.78) | EPHX2MTNR1AMTNR1BMAPK1HDAC8 | |
| SCHEMBL8562865 | 0.85 | EPHX2 (0.65) | EPHX2MTNR1AMTNR1BMAPK1HDAC8 | |
| SCHEMBL8561735 | 0.85 | EPHX2 (0.78) | EPHX2MTNR1AMTNR1BMAPK1HDAC8 | |
| SCHEMBL8562858 | 0.85 | EPHX2 (0.65) | EPHX2MTNR1AMTNR1BMAPK1HDAC8 | |
| SCHEMBL8561743 | 0.85 | EPHX2 (0.78) | EPHX2MTNR1AMTNR1BMAPK1HDAC8 | |
| SCHEMBL8562856 | 0.85 | EPHX2 (0.65) | EPHX2MTNR1AMTNR1BMAPK1HDAC8 | |
| SCHEMBL8567663 | 0.84 | EPHX2 (0.64) | EPHX2MTNR1AMTNR1BMAPK1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255109-A1 | Non-peptide GnRH antagonists | VANTIA, LTD | 2008-10-16 | — | — | US | disclosed |
| US-20080255109-A1 | Non-peptide GnRH antagonists | VANTIA, LTD | 2008-10-16 | — | — | US | disclosed |
| US-20080255109-A1 | Non-peptide GnRH antagonists | VANTIA, LTD | 2008-10-16 | — | — | US | disclosed |
| US-7365065-B2 | Non-peptide GnRH antagonists | FERRING B.V. (NL) | 2008-04-29 | — | — | US | disclosed |
| US-7365065-B2 | Non-peptide GnRH antagonists | FERRING B.V. (NL) | 2008-04-29 | — | — | US | disclosed |
| US-7365065-B2 | Non-peptide GnRH antagonists | FERRING B.V. (NL) | 2008-04-29 | — | — | US | disclosed |
| US-20050222139-A1 | Non-peptide gnrh antagonists | FERRING B.V. (NL) | 2005-10-06 | — | — | US | disclosed |
| EP-1485356-A1 | NON-PEPTIDE GnRH ANTAGONISTS | Ferring BV (NL) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003078398-A1 | NON-PEPTIDE GnRH ANTAGONISTS | FERRING BV (NL) | 2003-09-25 | — | — | WO | disclosed |
| US-5719141-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1998-02-17 | — | — | US | disclosed |
| EP-0702004-A2 | 2,9-diamino- and 2-amino-8-carbamoyl-4-hydroxy-alkanoic acid amid derivatives | CIBA-GEIGY AG (CH) | 1996-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222139-A1 | Non-peptide gnrh antagonists | GNRHR, BRS3, FSHR | EPHX2 3083/4885MTNR1A 59/4885MTNR1B 56/4885 |
| US-20080255109-A1 | Non-peptide GnRH antagonists | GNRHR, BRS3, FSHR | EPHX2 2925/4885MTNR1A 82/4885MTNR1B 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.